Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Symptoms and General Pathology

Diseases and Abnormalities at or Before Birth

Rare Diseases

Breast Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Genetic Predisposition to Disease

Disease Susceptibility

Hereditary Breast and Ovarian Cancer Syndrome

Carcinoma

Syndrome

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Disease Attributes

Neoplastic Syndromes, Hereditary

Genetic Diseases, Inborn

Breast Diseases

Skin Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

standardized data collection and 10-year prospective follow-up

Questionnaires

Dominique GENRE, MD

Margot BERLINE, MSc, MBA

Catherine NOGUES, MD

Cohort of subjects carrying a BRCA gene mutation: genetic predispositions to breast and ovarian cancers

Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation

risk that a subject with a mutation develops breast and / or ovarian cancer during his lifetime, assessed by epidemiologic questionnaires (carcinologic events).

UNICANCER - Le Groupe génétique et cancer (GGC)

Institut Paoli-Calmettes

Neoplasm Metastasis

Recurrence

Neoplastic Processes

Antineoplastic Agents

All Drugs and Chemicals

Dermatologic Agents

Immune Checkpoint Inhibitors

Immunomodulating Agents

Coal Tar

Keratolytic Agents

Group A (drug treatment group) : Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.

IFRT, IMRT or SBRT is applied. Irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent.

Drug therapy is the same as group A; IFRT is the same as group B.

Chemotherapy drugs ,targeted drugs or Immune checkpoint inhibitors are taken throughout the body or a combination of these drugs according to clinical needs is performed when necessary.

chemotherapy, targeted therapeutics, immunotherapy

IFRT（involving field radiotherapy） IMRT （ intensity modulated radiation therapy） SBRT （stereotactic body radiation therapy）

IFRT, IMRT or SBRT

Zi Liu, Ph.d

Jing Zhang, M.D

zi liu, Ph.D

In this study, The researchers sought to explore the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients among different groups which include drug therapy alone, radiotherapy alone, and drug therapy plus radiotherapy by inviting clinical multi-center participation.

The recurrent or refractory ovarian cancer tends to recur repeatedly at increasingly short intervals, making treatment more and more difficult.Patients often have limited physical capacity to undergo repeated systematic treatment. Currently, NCCN（ national comprehensive cancer network ）guidelines recommend palliative radiotherapy in patients with local recurrence of ovarian cancer. With the progress of IMRT（ intensity modulated radiation therapy ）, SBRT ( stereotactic body radiation therapy ) and other radiotherapy technologies, better local tumor control rate can also be achieved, while minimizing the damage to surrounding normal tissues. In this study, the patients will be divided into groups according to their wishes: group A (drug therapy alone), group B (radiotherapy alone), and group C (radiotherapy plus drug therapy).The researchers sought to explore the the efficacy and safety of involving field radiotherapy in the oligo-metastatic/recurrent/refractory ovarian cancer patients in different groups after treatment by inviting multiple centers to participate in the study.

Group A (drug treatment group) : Patients accept paclitaxel + platinum or paclitaxel single drug chemotherapy of which paclitaxel 135-175mg/m2, carboplatin AUC=5, cisplatin 40-60mg/m2. The treatment should be repeated every 3 weeks. Other second-line and third-line chemotherapy regimens (dose is not specified) are also allowed. Targeted, immunological or PARPi drugs can be added based on pathological and genetic test results until disease progression, unacceptable toxicity or informed consent withdrawal. Group B (radiotherapy group): IFRT, IMRT or SBRT is applied. Radiotherapy regimen: Involving field PGTV 60Gy-70Gy, 2-3Gy/f,5 times/week. External irradiation techniques and doses can be selected based on the previous experience of each center, but all patients enrolled within the center need to be consistent. Group C (radiotherapy + drug group) : IFRT is the same as group B;Drug therapy: same as group A.

Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer

LC will be measured from the start date of treatment until the date of progressive of the target lesion

PFS is defined as the time from first day of treatment until the first date of either objective disease progression or death due to any cause

OS is defined as the time from first day of treatment until the date of death due to any cause or the deadline for the study

Rate of acute and late adverse reactions associated with radiotherapy

Health Science Center of Xi'an Jiaotong University

Professor

Gautier CHENE

In this prospective study, patients who underwent vaginal hysterectomy with salpingectomy or salpingo-oophorectomy were included. The objective of this study is to assess the feasibility of prophylactic salpingectomy during vaginal hysterectomy for benign pathology and the prevalence of occult tubal lesions. The hypothesis is that prophylactic salpingectomy during vaginal hysterectomy for benign pathology present a low failure rate and it makes it possible to avoid the appearance of a certain number of ovarian cancers. The prevalence of bilateral salpingectomy with or without ovariectomy and the prevalence of histopathological and immunohistochemical (p53 expression) abnormalities were evaluated.

Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology

Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology and Evaluation of Occult Tubal Lesions Prevalence: Preliminary Study

prevalence of bilateral salpingectomy with or without ovariectomy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation	NCT03667417	Breast Cancers Ovarian Cancers	Questionnaires	18 Years -	Institut Paoli-Calmettes
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer	NCT05059782	Ovarian Cancer Neoplasm, Ovari... Ovarian Neoplas... Ovary Neoplasms Neoplasm, Ovary Neoplasms, Ovar... Ovary Neoplasm Neoplasms, Ovar... Ovary Cancer Cancer, Ovarian... Cancers, Ovary Ovary Cancers Cancer, Ovarian Cancers, Ovaria... Ovarian Cancers Cancer of Ovary Cancer of the O...	chemotherapy, t... IFRT, IMRT or S...	18 Years -	Health Science Center of Xi'an Jiaotong University
Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology	NCT03187327	Salpingectomy Hysterectomy		18 Years -	Hospices Civils de Lyon
Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation	NCT03667417	Breast Cancers Ovarian Cancers	Questionnaires	18 Years -	Institut Paoli-Calmettes
Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology	NCT03187327	Salpingectomy Hysterectomy		18 Years -	Hospices Civils de Lyon

Spots Global Cancer Trial Database for ovarian cancers